View Older Stories View More Recent Stories

Apr 12, 2019 12:45PM Arrowhead Presents Clinical Data on JNJ-3989 (ARO-HBV) at The International Liver Congress™
Apr 12, 2019 06:00AM Arrowhead Preclinical Data Demonstrates RNAi Therapy Prevents and Reverses Alpha-1 Liver Disease at The International Liver Congress™
Mar 29, 2019 04:30PM Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
Mar 18, 2019 07:34AM Arrowhead Pharmaceuticals Corp (ARWR) Reports IND Filing for Pivotal Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
Mar 18, 2019 07:30AM Arrowhead Pharmaceuticals Files IND for Pivotal Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
Mar 11, 2019 07:31AM Arrowhead Pharmaceuticals Corp (ARWR) Commences Dosing in Phase 1 Study of ARO-APOC3 for Treatment of Hypertriglyceridemia
Mar 11, 2019 07:30AM Arrowhead Pharmaceuticals Begins Dosing in Phase 1 Study of ARO-APOC3 for Treatment of Hypertriglyceridemia
Mar 1, 2019 07:30AM Arrowhead Pharmaceuticals to Present at Upcoming March 2019 Conferences
Feb 7, 2019 04:00PM Arrowhead Pharmaceuticals Reports Fiscal 2019 First Quarter Results
Jan 24, 2019 04:00PM Arrowhead Pharmaceuticals to Webcast Fiscal 2019 First Quarter Results
Jan 7, 2019 07:40AM Arrowhead Pharmaceuticals Corp (ARWR) Reports Filing of Regulatory Clearance to Begin Phase 1 Study of ARO-APOC3 for Treatment of Hypertriglyceridemia
Jan 7, 2019 07:31AM Arrowhead Pharmaceuticals Corp (ARWR) Reports First Patient Dosing in Phase 1 Study of ARO-ANG3 for Treatment of Dyslipidemias and Metabolic Diseases
Jan 7, 2019 07:30AM Arrowhead Pharmaceuticals Begins Dosing in Phase 1 Study of ARO-ANG3 for Treatment of Dyslipidemias and Metabolic Diseases
Jan 7, 2019 07:30AM Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-APOC3 for Treatment of Hypertriglyceridemia
Dec 17, 2018 06:06PM Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
Dec 11, 2018 04:00PM Arrowhead Pharmaceuticals Reports Fiscal 2018 Year End Results
Nov 27, 2018 07:30AM Arrowhead Pharmaceuticals to Webcast 2018 Fiscal Year End Results
Nov 9, 2018 12:00PM Arrowhead Pharma (ARWR) Presents Late-Breaking Preliminary Clinical Data on ARO-HBV at Liver Meeting
Nov 9, 2018 12:00PM Arrowhead Pharmaceuticals Presents Late-Breaking Clinical Data on ARO-AAT at Liver Meeting® 2018
Nov 9, 2018 12:00PM Arrowhead Pharmaceuticals Presents Late-Breaking Preliminary Clinical Data on ARO-HBV at Liver Meeting® 2018
Nov 1, 2018 07:30AM Arrowhead Pharmaceuticals to Present at Upcoming November 2018 Conferences
Oct 31, 2018 07:30AM Arrowhead Pharmaceuticals Announces Closing of Agreements with Janssen
Oct 16, 2018 12:01PM Arrowhead Pharmaceuticals Hosts R&D Day on Pipeline of RNAi Therapeutics
Oct 15, 2018 07:31AM Arrowhead Pharmaceuticals Corp (ARWR) Reports Filing for Regulatory Clearance to Begin Phase 1 Study of ARO-ANG3
Oct 15, 2018 07:30AM Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-ANG3
Oct 11, 2018 12:08PM Arrowhead Pharmaceuticals Corp (ARWR) to Present Late-Breaking Clinical Data on ARO-AAT and ARO-HBV at AASLD
Oct 11, 2018 12:05PM Arrowhead to Present Late-Breaking Clinical Data on ARO-AAT and ARO-HBV at AASLD Liver Meeting® 2018
Oct 4, 2018 07:32AM Arrowhead (ARWR) Announces $3.7 Billion License and Collaboration Agreements with Janssen (JNJ)
Oct 4, 2018 07:30AM Arrowhead Enters $3.7 Billion License and Collaboration Agreements with Janssen
Sep 25, 2018 07:30AM Arrowhead Pharmaceuticals to Present at Upcoming October 2018 Conferences
Sep 24, 2018 07:30AM Arrowhead Pharmaceuticals to Host R&D Day on Emerging Pipeline of RNAi Therapeutics
Sep 21, 2018 04:00PM Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
Sep 6, 2018 09:17AM Arrowhead Pharmaceuticals Corp (ARWR) to Present Positive ARO-HBV Clinical Data Demonstrating HBsAg Reductions
Sep 6, 2018 07:30AM Arrowhead Presents New ARO-HBV Clinical Data Demonstrating HBsAg Reductions at World Gastroenterologists Summit
Aug 31, 2018 07:31AM Arrowhead Pharmaceuticals Corp (ARWR) Reports Complete Dosing in Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
Aug 31, 2018 07:30AM Arrowhead Completes Dosing in Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
Aug 30, 2018 04:00PM Arrowhead Pharmaceuticals to Present at Upcoming September 2018 Conferences
Aug 7, 2018 04:00PM Arrowhead Pharmaceuticals Reports Fiscal 2018 Third Quarter Results
Aug 1, 2018 07:40AM Arrowhead Pharmaceuticals (ARWR) Reports $10 Million Milestone Payment from Amgen
Aug 1, 2018 07:30AM Arrowhead Pharmaceuticals Earns $10 Million Milestone Payment from Amgen
Jul 24, 2018 07:30AM Arrowhead Pharmaceuticals to Webcast Fiscal 2018 Third Quarter Results
Jun 29, 2018 07:31AM Arrowhead Pharmaceuticals Corp (ARWR) Highlights New Clinical Data on ARO-AAT at Alpha-1 National Education Conference
Jun 29, 2018 07:30AM Arrowhead Presents New Clinical Data on ARO-AAT at Alpha-1 National Education Conference
Jun 27, 2018 07:33AM Arrowhead Pharmaceuticals Corp (ARWR) Granted Positive EMA Opinion on Orphan Designation for ARO-AAT for Treatment of Congenital Alpha-1 Antitrypsin Deficiency
Jun 27, 2018 07:30AM Arrowhead Receives Positive EMA Opinion on Orphan Designation for ARO-AAT for Treatment of Congenital Alpha-1 Antitrypsin Deficiency
Jun 18, 2018 07:30AM Arrowhead Pharmaceuticals Corp (ARWR) Announces Complete Enrollment in Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
Jun 18, 2018 07:30AM Arrowhead Completes Enrollment in Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
Jun 8, 2018 04:30PM Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
May 30, 2018 07:39AM Arrowhead Pharmaceuticals Corp (ARWR) Reports Complete Enrollment in Single Dose Portion of Phase 1/2 Study of ARO-HBV
May 30, 2018 07:30AM Arrowhead Completes Enrollment in Single Dose Portion of Phase 1/2 Study of ARO-HBV
View More Recent Stories View Older Stories